SECTM1 Regulates Monocyte Levels and Is Associated With Incident Coronary Heart Disease

IF 8.4 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

JACC: Basic to Translational Science Pub Date : 2025-09-16 DOI:10.1016/j.jacbts.2025.101378

Usman A. Tahir MD , Daniel Cruz MD , Dongxiao Shen MS , Gaurav Tiwari MS , Jing Liu PhD , Matthew Huber MD , Christopher Chan MS , Shuliang Deng MS , Mark D. Benson MD , Jeremy Robbins MD , Zsu Zsu Chen MD , Laurie Farrell BS , Lynette Ekunwe MS , Michael Hall MD , Bruce M. Psaty MD , James S. Floyd MD , Aarti Asnani MD , Filip K. Swirski PhD , James G. Wilson MD , Robert E. Gerszten MD

{"title":"SECTM1 Regulates Monocyte Levels and Is Associated With Incident Coronary Heart Disease","authors":"Usman A. Tahir MD , Daniel Cruz MD , Dongxiao Shen MS , Gaurav Tiwari MS , Jing Liu PhD , Matthew Huber MD , Christopher Chan MS , Shuliang Deng MS , Mark D. Benson MD , Jeremy Robbins MD , Zsu Zsu Chen MD , Laurie Farrell BS , Lynette Ekunwe MS , Michael Hall MD , Bruce M. Psaty MD , James S. Floyd MD , Aarti Asnani MD , Filip K. Swirski PhD , James G. Wilson MD , Robert E. Gerszten MD","doi":"10.1016/j.jacbts.2025.101378","DOIUrl":null,"url":null,"abstract":"<div><div>Proteomic profiling may provide insights into new biomarkers and pathways in coronary heart disease (CHD). We profiled ∼1,300 proteins in 1,967 Black individuals in the Jackson Heart Study and found Secreted and Transmembrane Protein 1 (SECTM1), a monocyte chemoattractant, to be our top novel finding associated with incident CHD. We validated our findings in the Cardiovascular Health Study. The top variant (rs116473040) associated with SECTM1 was associated with circulating monocyte percentage of white blood cells in a genomic database. In vivo studies demonstrated that recombinant SECTM1a increased the proportion of proatherogenic Ly6Chi monocytes, suggesting a pathway by which SECTM1 may contribute to CHD.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"10 10","pages":"Article 101378"},"PeriodicalIF":8.4000,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC: Basic to Translational Science","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452302X25003316","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Proteomic profiling may provide insights into new biomarkers and pathways in coronary heart disease (CHD). We profiled ∼1,300 proteins in 1,967 Black individuals in the Jackson Heart Study and found Secreted and Transmembrane Protein 1 (SECTM1), a monocyte chemoattractant, to be our top novel finding associated with incident CHD. We validated our findings in the Cardiovascular Health Study. The top variant (rs116473040) associated with SECTM1 was associated with circulating monocyte percentage of white blood cells in a genomic database. In vivo studies demonstrated that recombinant SECTM1a increased the proportion of proatherogenic Ly6Chi monocytes, suggesting a pathway by which SECTM1 may contribute to CHD.

查看原文本刊更多论文

SECTM1调节单核细胞水平并与冠心病的发生有关

蛋白质组学分析可能为冠心病（CHD）的新生物标志物和途径提供见解。我们在杰克逊心脏研究中分析了1967名黑人个体的约1300种蛋白质，发现分泌和跨膜蛋白1 (SECTM1)，一种单核细胞化学引诱剂，是我们与冠心病事件相关的最高新发现。我们在心血管健康研究中证实了我们的发现。在基因组数据库中，与SECTM1相关的顶部变异（rs116473040）与循环单核细胞百分比相关。体内研究表明，重组SECTM1a增加了致动脉粥样硬化性Ly6Chi单核细胞的比例，提示SECTM1可能通过一种途径参与冠心病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JACC: Basic to Translational Science CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

14.20

自引率

1.00%

发文量

161

审稿时长

16 weeks

期刊介绍： JACC: Basic to Translational Science is an open access journal that is part of the renowned Journal of the American College of Cardiology (JACC). It focuses on advancing the field of Translational Cardiovascular Medicine and aims to accelerate the translation of new scientific discoveries into therapies that improve outcomes for patients with or at risk for Cardiovascular Disease. The journal covers thematic areas such as pre-clinical research, clinical trials, personalized medicine, novel drugs, devices, and biologics, proteomics, genomics, and metabolomics, as well as early phase clinical trial methodology.